CELG News
Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years
Bristol Myers Squibb (NYSE: BMY) today announced positive results through two years of treatment from the Phase 3 POETYK PsA-2 study, including its open-label extension (OLE), showing durable efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic...
Business Wire
Bristol Myers Squibb Announces Dividend
Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the company. The dividend is payable on November 2, 2026, to stockholders of record at the close of business...
Business Wire
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ...
Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel, in Patients with Quadruple-Class Exposed Relapsed and Refractory Multiple Myeloma Bristol Myers...
Business Wire
Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026
Bristol Myers Squibb (NYSE: BMY) today presented results from the EXPLORER-LTE cohort of the MAVA-LTE study (NCT03723655) in a late-breaker presentation at the European Society of Cardiology (ESC) Congress 2026 in Munich, Germany. EXPLORER-LTE is the largest and longest evaluation of symptomatic...
Business Wire
AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsAbbVie demonstrates resilient revenue growth fueled by its next-generation immunology and aesthetics portfolio...
Nasdaq News: Markets
U.S. FDA Grants Accelerated Approval to Bristol Myers Squibb's First CELMoD Therapy ZENBEXUS, in Combination with Daratumumab and Hyaluronidase-fihj and Dexamethasone (ZDd) for Patients with Multiple Myeloma, as Early as First Relapse
Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple myeloma who have received at least...
Business Wire
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration PR Newswire SAN DIEGO, Aug. 13, 2026 SAN DIEGO...
PR Newswire
Bristol Myers Squibb Advances U.S. Manufacturing Investment with New $2.3 Billion Campus in Houston, Texas
Bristol Myers Squibb (NYSE:BMY) today announced the selection of Houston, Texas, as the site for a new, state-of-the-art multi-modal manufacturing campus, representing an approximately $2.3 billion investment designed to accelerate the delivery of next-generation medicines to patients. The campus...
Business Wire
Bristol Myers Squibb Reports Second Quarter Financial Results for 2026
Bristol Myers Squibb (NYSE: BMY) today reported second quarter 2026 financial results. Visit the companys Investor Relations website at http://investor.bms.com to view the detailed second quarter 2026 earnings press release and investor presentation. The company will host a conference call and live...
Business Wire
Apple, Microsoft And 3 Stocks To Watch Heading Into Thursday
U.S. stock futures trading higher, focus on Apple, Microsoft, Amazon earnings. Meta posts mixed results, Bristol-Myers Squibb to release earnings.read more...
Benzinga